首页> 外国专利> MODIFIED RELEASE ORAL COMPOSITION COMPRISING BIOAVAILABLE 5-ASA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

MODIFIED RELEASE ORAL COMPOSITION COMPRISING BIOAVAILABLE 5-ASA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

机译:改良的含生物活性5-ASA的释药口服组合物,用于治疗炎症性肠病

摘要

A modufied release oral composition for the treatment of inflammatory bowel diseases, said composition ensuring bioavailability of 5-aminosalicylic acid (5-ASA) in both the small and large intestine, and consisting of individually coated granules, each granule comprising: a core consisting essentially of 5-aminosalicylic acid (5-ASA) or a pharmaceutically acceptable salt or ester thereof and a physiologically acceptable spheronization aid, preferably a cellulose derivative, in particular microcrystalline cellulose, and a coating confining said core, said coating comprising a rate- limiting barrier-material, preferably a semi-permeable polymer, in particular ethylcellulose; and the majority of the granules, preferably more than 80%, more preferably more than 90%, of the granules being essentially spherical as defined by an aspect ratio (defined as the ratio of the length divided by the breadth) within 1.00-1.25, preferably within 1.00-1.20, more preferably within 1.00-1.15; and the majority of the granules, preferably more than 70%, more preferably more than 90%, of the individual granules of the composition exerting sieve values in the range of O0.5 mm and l 1.4, mm, preferably in the rang of O0.7 mm and o1.1; and the composition exerting the following in vitro dissolution rates [when measured in a model sytem using simulated intestinal fluid in USP Paddle System 2 operated at 37oC with stirring speed 100 rpm]: (a) within 2-20%, preferably within 5-15%, of the total 5-ASA is released after 15 minutes in the model system; (b) within 20-50%, preferably within 25-45%, of the total 5-ASA is released after 60 minutes in the model system; (c) within 30-70%, preferably within 40-60% of the total 5-ASA is released after 90 minutes in the model system; (d) within 50-90%, preferably within 55-80%, of the total 5-ASA is released after 150 minutes in the model system; (e) within 75-100% of the total 5-ASA is released after 240 minutes in the model system. 4352 ח' באדר ב' התשס" ג - March 12, 2003
机译:一种用于治疗炎性肠疾病的改良释放的口服组合物,所述组合物确保5-氨基水杨酸(5-ASA)在小肠和大肠中的生物利用度,并且由单独包衣的颗粒组成,每个颗粒包括:核心,基本上由核心组成5-氨基水杨酸(5-ASA)或其药学上可接受的盐或酯和生理上可接受的滚圆助剂,优选纤维素衍生物,特别是微晶纤维素,和限制所述核的涂层,所述涂层包含限速屏障-材料,优选为半渗透性聚合物,特别是乙基纤维素;并且大多数颗粒,优选大于80%,更优选大于90%,基本上是球形的,由纵横比(定义为长度除以宽度的比)限定在1.00-1.25之间,优选在1.00-1.20之内,更优选在1.00-1.15之内;并且大多数颗粒,优选大于该组合物的单个颗粒的70%,更优选大于90%,其筛分值在O0.5mm至l1.4mm的范围内,优选在O0的范围内.7毫米和o1.1;以及具有以下体外溶出速率的组合物[当在模型系统中使用模拟肠道液在37oC,100 rpm搅拌速度下于USP Paddle System 2中进行测量时]:(a)2-20%,优选5-15 15分钟后,在模型系统中释放了全部5-ASA中的%; (b)在模型系统中60分钟后释放的5-ASA总量的20-50%之内,最好是25-45%之内; (c)在模型系统中90分钟后释放的5-ASA总量在30-70%之内,最好在40-60%之内; (d)在模型系统中放置150分钟后,释放的5-ASA总量在50-90%之内,最好在55-80%之内; (e)在模型系统中放置240分钟后,释放了5-ASA总量的75-100%。 4352ח'באדרב'התשס“”-2003年3月12日

著录项

  • 公开/公告号IL124858B

    专利类型

  • 公开/公告日2003-03-12

    原文格式PDF

  • 申请/专利权人 FARMACEUTISK LABORATORIUM FERRING A/S;

    申请/专利号IL124858

  • 发明设计人

    申请日1998-06-11

  • 分类号

  • 国家 IL

  • 入库时间 2022-08-22 00:02:43

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号